Cholinergic Agonist Modulation of Pancreatic Tumor Stroma

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for pancreatic cancer, particularly pancreatic adenocarcinoma (PDAC), are ineffective due to the supportive role of the surrounding stroma and the limited success of cytotoxic drugs in achieving long-term survival, necessitating a novel therapeutic approach.

Innovation Solution

Administration of a cholinergic agonist, such as bethanechol, pilocarpine, or McN-34A, either alone or in combination with surgery and chemotherapy, to inhibit the proliferation of pancreatic tumor cells, reduce metastasis, and target cancer stem cells by modulating muscarinic receptor signaling.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If cytotoxic drugs are administered for pancreatic cancer treatment, then tumor cell death is achieved, but significant toxicity and failure to achieve long-term survival occur

Engineering Contradiction:

Improvelong-term survivalVSAvoidtoxicity

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses cholinergic agonists as intermediary substances that modulate the tumor microenvironment and stromal cells rather than directly killing tumor cells. This indirect approach reduces toxicity while maintaining therapeutic efficacy, as the agonists target the supportive stromal network that sustains tumor growth rather than attacking rapidly dividing tumor cells directly

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes the therapeutic parameter from direct cytotoxicity to cholinergic receptor modulation. By administering cholinergic agonists that bind to muscarinic receptors on stromal and tumor cells, the treatment shifts from non-specific cell killing to targeted modulation of cellular signaling pathways, thereby reducing off-target toxicity while achieving anti-tumor effects

Inventive Principle:

Principle #35Parameter changes

2Reliability

If standard chemotherapy is used, then some tumor cell death occurs, but the surrounding stroma sustains the tumor and treatment fails

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidstroma support

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent extracts and targets the stromal component as the primary therapeutic focus rather than the tumor cells themselves. By administering cholinergic agonists that specifically modulate stromal cell behavior and reduce their tumor-supportive functions, the treatment removes the protective stromal barrier that enables tumor survival and resistance to conventional therapy

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent converts the previously harmful stromal support into a therapeutic target. The stroma, which normally sustains tumor growth, becomes the focus of cholinergic agonist action, where modulation of stromal cholinergic receptors transforms the stromal environment from tumor-promoting to tumor-suppressive, thereby converting a protective factor into a vulnerability

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Data Source

PatentUS11344534B2Cholinergic agonism for the treatment of pancreatic cancer

Publication Date: 2022.05.31 THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK

AI summary

The invention provides for methods for treating pancreatic cancer, reducing or inhibiting pancreatic tumor cells, inhibiting or treating pancreatic cancer metastases, and inhibiting pancreatic cancer stem cell growth in a subject by administering a cholinergic agonist.